SECUKINUMAB IN PSORIASIS: RESULTS FROM A SINGLE-CENTER DATABASE

Sanjid Ahammed Eramasam Veedu, Wu Jianbo and Xie Jun*

ABSTRACT

Introduction: Due to the blanket immune damp down of conventional psoriasis therapies, secukinumab; a targeted IL-17 receptor inhibitor was introduced to manage moderate to severe psoriasis. This study aimed to ascertain the efficacy and safety of secukinumab either alone or in combination with topical agents, for managing psoriasis. Methods: A retrospective observational study was conducted at Zhongnan Hospital of Wuhan University from October 2021 to January 2023. Secukinumab therapy was analyzed in 91 moderate to severe psoriasis patients. Data was analyzes in SPSS using independent sample t-test and Parsons’s Chi-square of Fischer’s exact test. Results: A total of 91 psoriasis patients were analyzed; 69 (75.8%) males, and a mean (±SD) age of 45.8±15.7 years. Mean (±SD) baseline PASI score was 13.12±6.6. At 48 week, response to treatment as measured by PASI 50, 75, and 90 response rates were 28.6%, 7.1% and 3.6% for secukinumab monotherapy and 44.4%, 6.7% and 6.3% for secukinumab & topical combination therapy respectively. Only PASI 50 was statistically significant between the two groups. This finding suggest that combination of secukinumab & topical therapy was more effective than monotherapy. At 48 weeks, the PASI 50, 75, and 90 response rates were 13.1%, 4.7%, and 2.4% in biologics naïve patients versus 14.3%, 0%, and 0% in non-biologics naïve ones respectively, suggesting better response in biologics naïve patients. Conclusion: Combination of secukinumab & topical agent was safe and more effective than secukinumab monotherapy. Biologics naïve patients respond better to secukinumab than those pre-exposed to biologics.

Keywords: Secukinumab, psoriasis, biologic treatment, efficacy, safety.